Approval · Notice of Compliance 2120 · 2001
CANCIDAS: Notice of Compliance 2120
Issued July 19, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2120
- Date
- July 19, 2001
- Company
- Merck Frosst Canada & Cie, Merck Frosst Canada & Co.Kirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
- Therapeutic class
- Antifungal
Products in this notice
Medicinal ingredients
- CASPOFUNGIN ACETATE 50 MG per VIAL
- CASPOFUNGIN ACETATE 70 MG per VIAL